Juan Sanchez
Dr. Juan F. Sanchez is a vice president at Ladenburg Thalmann & Co. Inc, Research Division. He covers biotechnology and nanotechnology sectors with a focus on central nervous system therapeutics. Dr. Sanchez's previous experience includes oncology marketing at Bristol Myers Squibb and post-genomic strategy planning at the Office of the Vice Provost, Columbia University. He has five years of experience in clinical medical practice. Dr. Sanchez received a Master in International Affairs from Columbia University, a Master of Business Administration from University of Los Andes and a Medical Doctor degree from Javeriana University.
Recent Quotes
"We believe the ADX71149 program could be potentially transformative for ADXN."
—
Juan Sanchez, Ladenburg Thalmann
(2/8/13)
more >
"ADXN has two assets addressing real medical needs in midstage clinical development."
—
Juan Sanchez, Ladenburg Thalmann
(11/5/12)
more >
"We reiterate our Buy rating on ADXN."
—
Juan Sanchez, Ladenburg Thalmann
(8/29/12)
more >
"We reiterate our Buy rating on ADXN."
—
Juan Sanchez, Ladenburg Thalmann
(8/22/12)
more >
"Data show ADXN's dipraglurant is safe and active (in treating LID)."
—
Juan Sanchez, Ladenburg Thalmann
(6/21/12)
more >
"Positive data from a phase 2 study of ADX71149 could be transformative for ADXN."
—
Juan Sanchez, Ladenburg Thalmann
(6/5/12)
more >
"New findings highlight dipraglurant's potential positioning; ADXN is a Buy."
—
Juan Sanchez, Ladenburg Thalmann
(12/6/11)
more >
"ADXN is advancing its internal pipeline, generating important partnerships."
—
Juan Sanchez, Ladenburg Thalmann
(8/16/11)
more >